Rapid Readouts: Phase 3 HERO Trial

October 8, 2020

Neal D. Shore, MD, FACS, Carolina Urologic Research Center

Video

Supported by an unrestricted educational grant from Myovant Sciences.

Related Videos

Josep Maria Piulats Rodriguez, MD, PhD

Phillip J. Koo, MD

Phillip J. Koo, MD

Gautam Jha, MD

Emmanuel Antonarakis, MD, and Gautam Jha, MD

Daniel Spratt, MD

James Knight, MD

Related Content

Ebrahim Delpassand, MD, of Excel Diagnostics and Nuclear Oncology Center

PSMA-Directed Targeted Alpha Therapy Shows Activity in Heavily Pretreated Metastatic CRPC

April 10th 2024

Neeraj Agarwal, MD

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Ruben Olivares, MD

Patient Selection Key for Focal Therapy in Intermediate Prostate Cancer

Andrew J. Armstrong, MD, MSc

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Daniel Spratt, MD, of University Hospitals Seidman Cancer Center and Case Western Reserve University

Metastasis-Directed Radiotherapy Represents Significant Advancement in Prostate Cancer

Phillip J. Koo, MD, chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Phoenix, Arizona

Recommendations Further Aid in Elucidating the Role of PSMA PET Imaging in Prostate Cancer

Related Content

Ebrahim Delpassand, MD, of Excel Diagnostics and Nuclear Oncology Center

PSMA-Directed Targeted Alpha Therapy Shows Activity in Heavily Pretreated Metastatic CRPC

April 10th 2024

Neeraj Agarwal, MD

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Ruben Olivares, MD

Patient Selection Key for Focal Therapy in Intermediate Prostate Cancer

Andrew J. Armstrong, MD, MSc

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Daniel Spratt, MD, of University Hospitals Seidman Cancer Center and Case Western Reserve University

Metastasis-Directed Radiotherapy Represents Significant Advancement in Prostate Cancer

Phillip J. Koo, MD, chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Phoenix, Arizona

Recommendations Further Aid in Elucidating the Role of PSMA PET Imaging in Prostate Cancer

Latest Conference Coverage

Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC

Adjuvant Nivolumab Provides Sustained DFS Benefit, Favors OS in Muscle-Invasive Urothelial Cancer

Simulations Improve CAR T-Cell Therapy Understanding and Administration Confidence

Orca-T May Be a Suitable Option Over PTCy-Based HSCT in Acute Leukemia and MDS

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.